Top-down approaches are exemplified by the discovery of NRF2 activations, which were detected in all lung cancer tissues regardless of the status of other biomarkers, such as EGFR, ALK, ROS-1 and other genetic alterations. The gene discussed is NFE2L2; the disease is lung carcinoma.